Yes, closetinvestor, figure 7 shows the results of a particular measurement "P300 amplitude performance". It only shows data at 1 month for the 2-73 patients (change +38%), but also shows the donepezil data up to 6 months peaking at +34%. So the 2-73 patients improved quickly (1 month) and were slightly better than the donepezil patients at 6 months.
But as Doc328 pointed out, the 2-73 data only goes out to 1 month, so we do not know how they would compare, both at 6 months or 1 year. He noted that investor provided a link for the 2-73 data up to 1 year, but because it did not make sense, this test was not included in the phase2a/3 trial.
News 
Market Data 
Discover 
